趋化因子Fractalkine在动脉粥样硬化过程中的作用机制及辛伐他汀干预效应的实验研究
|
摘要
背景
Fractalkine(FKN)是一具有粘附活性的趋化因子。膜结合型FKN独特的粘蛋白样杆状结构凸出细胞膜表面,使其易粘附流动的白细胞。并且,FKN介导的粘附反应不需要选择素(selectin)和整合素(integrin)等其他黏附分子的参与。FKN蛋白跨膜区N端有一段特殊的保守部位,即由Thr-Arg-Arg-Gln组成的二元断裂位点(dibasiccleavage site),在此断裂位点被蛋白水解酶水解脱落,形成可溶FKN,发挥趋化效应。FKN独特的结构和功能使其广泛参与炎症反应。慢性炎症反应是动脉粥样硬化(atherosclerosis,AS)的重要重要机制之一,白细胞越过血管向炎症部位移行是炎症反应中重要的生物学现象。单核细胞是AS中泡沫细胞的前体细胞,在向炎症部位迁移的过程中需要趋化因子和黏附分子的参与。近年来的研究资料表明,FKN参与了AS的发生发展。
白细胞介素—18(Interleukin-18,IL-18)是重要的炎症因子,是动脉粥样硬化明确的危险因素。其在冠状动脉粥样硬化性心脏病的发生、发展及粥样斑块破裂等过程中发挥重要作用。以往的研究多认为,IL-18与AS的密切关系主要是通过干扰素-γ(interferon-γ,IFN-γ)实现的。而且,在IFN-γ缺失的情况下,IL-18的相关功能则无法体现。但近期的研究表明,在没有IFN-γ的参与下,IL-18也可以参与AS的炎症过程。IL-18与IL-18R结合导致多种与动脉粥样硬化相关的细胞因子如IL-6、IL-8、细胞黏附分子-1和多种基质金属蛋白酶(MMPs)分泌增加。然而,IL-18能否诱导和上调FKN的表达,并通过FKN的趋化和粘附功能参与炎症反应,及其机制尚不清楚。
辛伐他汀(Simvastatine,Sim)是由土曲霉菌降解产物合成的三羟基三甲基戊二酰辅酶A还原酶抑制剂,广泛用于冠心病的预防和治疗。除降脂外,还具有改善内皮功能,改善心肌缺血,抗炎、抗血栓,稳定动脉粥样硬化斑块等作用。Sim能否通过影响FKN的表达而发挥抗炎、稳定斑块的作用尚不明确。
目的
(1)应用IL-18作为刺激因素,探讨IL-18能否诱导脐静脉内皮细胞(HUVEC)上调表达FKN,明确两者的作用关系及信号通路;
(2)应用Transwell进行体外趋化试验,观察FKN对巨噬细胞源性单核细胞株(THP-1)的趋化作用;
(3)应用Flow chamber模拟人体生理血流环境,观察FKN介导的HUVECs和THP-1细胞的粘附;
(4)探讨辛伐他汀对FKN表达的影响,以及对FKN趋化和粘附作用的干预效应。
方法
(1)HUVECs与100 ug/L的IL-18孵育0、1、6、12、24小时,半定量RT-PCR方法检测FKN的mRNA表达;
(2)HUVECs分别与浓度为0ug/L、25 ug/L、50 ug/L、100 ug/L的IL-18共孵育24小时,半定量RT-PCR方法检测FKN的mRNA表达;
(3)预先用10umol/L、30umol/L的PDTC预处理HUVECs,再用100ug/L的IL-18刺激24小时,半定量RT-PCR方法检测FKN的mRNA表达;
(4)预先用1umol/ml、10umol/ml、100umol/ml的辛伐他汀预处理HUVECs,再用100ng/L的IL-18刺激24小时,半定量RT-PCR方法检测细胞FKN的mRNA表达;
(5)HUVECs与0ug/L、25 ug/L、50 ug/L、100 ug/L的IL-18孵育24小时;10umol/L、30umol/L的PDTC预处理HUVECs,再用100ug/L的IL-18刺激24小时;预先用10umol/ml、100umol/ml的辛伐他汀预处理HUVECs,再用100ng/L的IL-18刺激24小时;100 ug/L的IL-18刺激HUVECs 24小时后,用1umg/L、5ug/L的FKN中和抗体作用3小时。应用Transwell装置观察FKN对THP-1细胞的趋化效应;
(6)HUVECs与0ug/L、25 ug/L、50 ug/L、100 ug/L的IL-18孵育24小时;10umol/L、30umol/L的PDTC预处理HUVECs,再用100ug/L的IL-18刺激24小时;预先用10umol/ml、100umol/ml的辛伐他汀预处理HUVECs,再用100ng/L的IL-18刺激24小时;100 ug/L的IL-18刺激HUVECs 24小时后,用1umg/L、5ug/L的FKN中和抗体作用3小时。应用Flow chamber装置观察FKN在模拟生理血流环境下介导的HUVEC与THP-1细胞的粘附。
结果
(1)HUVECs与100ug/L的IL-18孵育1小时后,FKN表达无明显增加,与空白对照组相比p＞0.05;HUVECs与100ug/L的IL-18孵育6、12、24小时后,FKN的基因表达明显增加,与空白对照组比较p＜0.01;
(2)HUVECs与5ug/L的IL-18孵育24小时后,FKN表达量无明显增加,与空白对照组相比p＞0.05;HUVECs与25 ug/L、50 ug/L、100 ug/L的IL-18孵育24小时后,FKN的基因表达明显增加,与空白对照组比较p＜0.01;
(3)用10umol/L、30umol/L的PDTC预处理HUVEC后,再加入100ug/L的IL-18孵育24小时,FKN表达量明显减少,与未经PDTC处理的单纯100ug/L IL-18刺激组比较p＜0.01;
(4)用1 umol/L的辛伐他汀预处理HUVECs后,再加入100ug/L的IL-18孵育24小时,FKN表达量无明显变化,与单纯100ug/L IL-18刺激组比较p＞0.05;用10umol/L、100umol/L辛伐他汀预处理HUVEC后,再加入100ug/L的IL-18孵育24小时,FKN表达量明显减少,与未经辛伐他汀处理的单纯100ug/L IL-18刺激组比较p＜0.01。
(5)成功使用Tranwell装置进行了体外趋化试验;FKN能够趋化静息的THP-1细胞;
(6)不同浓度IL-18上调FKN表达后,对THP-1细胞的趋化效应明显增强,与对照组比较p＜0.01;PDTC、辛伐他汀预处理HUVEC后,该趋化效应明显减弱,与单纯IL-18刺激组相比p＜0.01;FKN中和抗体能够抑制FKN介导的趋化作用,与单纯IL-18刺激组相比p＜0.01。
(7)成功应用Flow chamber在体外模拟了人体生理状态的血液循环条件进行粘附实验;使用EDTA阻断其他黏附分子的参与后,FKN以非钙离子依赖的方式介导了HUVECs与单核细胞THP-1的粘附;
(8)不同浓度IL-18上调FKN表达后,THP-1细胞与HUVEC的粘附明显增加,与对照组比较p＜0.01;PDTC预处理HUVEC后,该粘附效应明显减弱,与单纯IL-18刺激组相比p＜0.01。FKN中和抗体能够抑制FKN介导的粘附作用,与单纯IL-18刺激组相比p＜0.01。10umol/ml的辛伐他汀预处理HUVEC后,未能明显抑制FKN介导的粘附反应,与单纯IL-18刺激组相比p＞0.05。100umol/ml的辛伐他汀能够明显抑制该粘附效应,与单纯IL-18刺激组相比p＜0.01。
结论
(1)IL-18能够呈浓度、时间依赖性上调FKN的基因表达。这种诱导作用与NF-KB信号转导途径有关;
(2)FKN能够趋化静息THP-1细胞,IL-18能够增加THP-1细胞的迁移;
(3)在模拟生理血液循环的条件下,FKN能够介导HUVECs与静息THP-1细胞的粘附,IL-18能够增强该粘附反应;
(4)辛伐他汀能够抑制IL-18诱导HUVECs上调表达FKNmRNA,抑制FKN介导的趋化及粘附作用。
Background
Fractalkine(FKN) is a membrane-tethered chemokine that functions as chemokines and adhesion molecules to capture and induce firm adhesion of a subset of leukocytes in a selectin- and integrin -independent manner.Soluble FKN can be released,presumably by proteolysis at a membrane-proximal dibasic cleavage site(Thr-Arg- Arg-Gln),and exhibits an efficient chemotactic activity for monocytes.The novel structure and functions of FKN suggest that it may play a key role in the multistep process of leukocyte trafficking,while raising several issues. Chronic inflammation is one of the mechanism of Atherosclerosis (AS).The migration of leukocyte through intima is an essential biological phenomena of inflammation.Monocytes are important cells for forming the foam cells.The primary step of this is to migrate through intima too.The molecular control of these essential trafficking events requires two broad classes of molecules:various cell adhesion molecules,as well as leukocyte chemotactic factors,the chemokine superfamily.Now we have increasingly more evidence that FKN participate in the formation and development of atherosclerosis(AS).
In recent years,increasing evidences has emerged from experimental and epidemiological data that interleukin- 18(IL- 18),a pro-inflammatory cytokinee involved in both innate and acquired immune responses,plays a key role in the inflammatory response that contributes to AS.Baseline circulating IL-18 levels were strongly predictive of future cardiovascular disease.Most past studies suggest that IL-18 function mainly through interferon-γ(IFN -γ),and could not intervene AS without IFN-γ.Recent studies make it clear that IL-18 could also mediate several reactions in a IFN -γindependent manner.Banding of IL-18 and IL-18 receptor enhances the secretion of IL-6、IL-8、ICAM-1 and MMPs.However,it remains unclear whether IL-18 up-regulate the expression of FKN,and participate AS through the chemotactic and adhesive function of FKN.
Simvastatin is the 3-hydroxy-3-methylglutanyl coenzyme A(HMG-CoA) reductase inhibitor lipid-lowering agents synthesized from degradation products of aspergillus terreus.It has been used as one of the important medicine for coronary heart diseases.Besides lipid-lowering function,Simvastatin could protect endothelial cells,improve myocardial ischemia,anti-inflammatory anti-thrombosis and stabilize atherosclerotic plaques.However,it is still unclear whether Simvastatin exert its role through effect the expression and chemotactic,adhesive function of FKN.
Objective
(1)To observe the expression of FKN induced by IL-18 in HUVECs, and to investigate its signal pathway.
(2)Using Transwell to observe the chemotaxis of FKN and the effect of IL- 18 on monocyts migration;
(3)Using in vitro Flow chamber mimic the vivo fluid dynamic environment to observe the adhesion between HUVECs and THP-lcells mediated by FKN and the effect of IL-18;
(4)To investigate the effect of Simvastatine on expression of Fractalk -ine upregulated by IL-18,and the interventional effect on chemotaxis, adhesive function of FKN.
Methods
(1) HUVECs were cultured and treated with IL-18 of concentrations 100μg/L for 0,1,6,12,24 hours.FKN mRNA expressions were determined by semi-quantitative reverse-transcription polymerase chain reaction(RT-PCR).
(2) HUVECs were cultured and treated with IL-18 of 4 different concentrations(5μg/L,25μg/L,50μg/L,and 100μg/L) for 24 hours.We determined mRNA expressions of FKN by semi-quantitative reverse-transcription polymerase chain reaction(RT-PCR).
(3) Pretreated HUVECs with PDTC(A specific inhibitor of NF-KB) of 2 different concentrations(10umol/L,30umol/L),then cells were treated with IL-18(100ug/L) for 24 hours,mRNA expressions of FKN were determined by semi-quantitative RT-PCR.
(4)Pretreated HUVECs with Simvastatine of 3 different concentrations (1 umol/L,10umol/L,100umol/L),then cells were treated with IL- 18 (100ug/L) for 24 hours.FKN mRNA expressions were determined by semi-quantitative RT-PCR.
(5) HUVECs were treated as above 1,3,4 method.The other HUVECs were cultured and treated with IL- 18 of 100 ug/L for 24 hours, then cells were treated with neutralizing antibody of FKN(1 ug/L,5ug/L) for 2 hours.The migration of THP-1 cells mediated by FKN was odserved by Transwell.
(6) HUVECs were treated as above 1,3,4 method.The other HUVECs were cultured and treated with IL- 18 of 100 ug/L for 24 hours, then cells were treated with neutralizing antibody of FKN(1ug/L,5ug/L) for 2 hours.The adhesion of HUVECs and THP-1 cells mediated FKN was odserved by In vitro Flow chamber assay.
Results
(1) HUVECs cultured and incubated with 100ug/L IL- 18 for 1 hour resulted in no difference of FKNmRNA expression as compared with control group(p＞0.05);HUVECs were cultured and incubated with IL-18 of concentrations 100μg/L for 6,12,24 hours resulted in upregulated expression of FKNmRNA,as compared with control group (p＜0.01);
(2) HUVECs cultured and incubated with 5ug/L IL-18 for 24 hours resulted in no difference of FKNmRNA expression,as compared with control group(p＞0.05);HUVECs were cultured and incubated with IL-18 of concentrations 25,50,100μg/L for 24 hours resulted in upregulated expression of FKNmRNA,as compared with control group(p＜0.01);
(3) Pretreated HUVECs with PDTC of 10umol/L,30umol/L and then incubated with IL-18(100ug/L) for 24h resulted in downregulated expression of FKN mRNA,as compared with the pure IL-18(100ug/L) group(p＜0.01);
(4) Pretreated HUVECs with Simvastatin of 1umol/L and then incubated with IL-18(100ug/L) for 24h resulted in no difference of FKNmRNA expression,as compared with the pure IL-18(100ug/L) group (p＞0.05);Pretreated HUVECs with Simvastatin of 10umol/L and 100umol/L and then incubated with IL-18(100ug/L) for 24h resulted in down-regulated expression of FKN mRNA,as compared with the pure IL-18(100ug/L) group(p＜0.01).
(5)The chemotactic assay was successful by using Transwell,FKN could chemotaxis the resting THP-1 cells;
(6) After up-regulated FKN mRNA expression induced by IL-18 with different concentrations,the chemotactic effect of FKN to THP-1 cells were enhanced significantly,consistent to the expression of FKN mRNA.The chemotactic effect were inhibited if HUVECs pretreated with Simvastatin or PDTC,or treated with neutralizing antibody,as compared with the pure IL-18(100ug/L) group(p＜0.01)
(7)Using in vitro flow chamber mimic the vivo fluid environment secessfully,FKN could mediate the adhesion in a Ca~(2+) independent maner;
(8) After up-regulated FKN mRNA expression induced by IL- 18,the adhesion mediated by FKN was enhanced significantly,as compared with control group(p＜0.01).The adhesion were inhibited after HUVECs pretreated with PDTC,or treated with neutralizing antibody,as compared with pure IL-18(100ug/L) group(p＜0.01).Simvastatin with 10umol/ml concentration did not inhibit the adhesion,as compared with the pure IL-18(100ug/L) group(p＞0.05).Simvastatin with concentration of 100umol/L inhibated the adhesion,as compared with the pure IL- 18(100ug/L) group(p＜0.01).
Conclusions
(1) IL-18 could up-regulate the expression of FKN mRNA in a dose-and time-dependent manner,and this effect might be related to NF-KB.
(2) IL-18 could enhance the chemotactic and adhesive effect of HUVECs to THP-1 cells significantly by up- regulation of FKN.
(3) Simvastatin could down-regulated the expression of FKN mRNA induced by IL-18,and inhabit the chemotactic and adhesion.
Fractalkine(FKN)是一具有粘附活性的趋化因子。膜结合型FKN独特的粘蛋白样杆状结构凸出细胞膜表面,使其易粘附流动的白细胞。并且,FKN介导的粘附反应不需要选择素(selectin)和整合素(integrin)等其他黏附分子的参与。FKN蛋白跨膜区N端有一段特殊的保守部位,即由Thr-Arg-Arg-Gln组成的二元断裂位点(dibasiccleavage site),在此断裂位点被蛋白水解酶水解脱落,形成可溶FKN,发挥趋化效应。FKN独特的结构和功能使其广泛参与炎症反应。慢性炎症反应是动脉粥样硬化(atherosclerosis,AS)的重要重要机制之一,白细胞越过血管向炎症部位移行是炎症反应中重要的生物学现象。单核细胞是AS中泡沫细胞的前体细胞,在向炎症部位迁移的过程中需要趋化因子和黏附分子的参与。近年来的研究资料表明,FKN参与了AS的发生发展。
白细胞介素—18(Interleukin-18,IL-18)是重要的炎症因子,是动脉粥样硬化明确的危险因素。其在冠状动脉粥样硬化性心脏病的发生、发展及粥样斑块破裂等过程中发挥重要作用。以往的研究多认为,IL-18与AS的密切关系主要是通过干扰素-γ(interferon-γ,IFN-γ)实现的。而且,在IFN-γ缺失的情况下,IL-18的相关功能则无法体现。但近期的研究表明,在没有IFN-γ的参与下,IL-18也可以参与AS的炎症过程。IL-18与IL-18R结合导致多种与动脉粥样硬化相关的细胞因子如IL-6、IL-8、细胞黏附分子-1和多种基质金属蛋白酶(MMPs)分泌增加。然而,IL-18能否诱导和上调FKN的表达,并通过FKN的趋化和粘附功能参与炎症反应,及其机制尚不清楚。
辛伐他汀(Simvastatine,Sim)是由土曲霉菌降解产物合成的三羟基三甲基戊二酰辅酶A还原酶抑制剂,广泛用于冠心病的预防和治疗。除降脂外,还具有改善内皮功能,改善心肌缺血,抗炎、抗血栓,稳定动脉粥样硬化斑块等作用。Sim能否通过影响FKN的表达而发挥抗炎、稳定斑块的作用尚不明确。
目的
(1)应用IL-18作为刺激因素,探讨IL-18能否诱导脐静脉内皮细胞(HUVEC)上调表达FKN,明确两者的作用关系及信号通路;
(2)应用Transwell进行体外趋化试验,观察FKN对巨噬细胞源性单核细胞株(THP-1)的趋化作用;
(3)应用Flow chamber模拟人体生理血流环境,观察FKN介导的HUVECs和THP-1细胞的粘附;
(4)探讨辛伐他汀对FKN表达的影响,以及对FKN趋化和粘附作用的干预效应。
方法
(1)HUVECs与100 ug/L的IL-18孵育0、1、6、12、24小时,半定量RT-PCR方法检测FKN的mRNA表达;
(2)HUVECs分别与浓度为0ug/L、25 ug/L、50 ug/L、100 ug/L的IL-18共孵育24小时,半定量RT-PCR方法检测FKN的mRNA表达;
(3)预先用10umol/L、30umol/L的PDTC预处理HUVECs,再用100ug/L的IL-18刺激24小时,半定量RT-PCR方法检测FKN的mRNA表达;
(4)预先用1umol/ml、10umol/ml、100umol/ml的辛伐他汀预处理HUVECs,再用100ng/L的IL-18刺激24小时,半定量RT-PCR方法检测细胞FKN的mRNA表达;
(5)HUVECs与0ug/L、25 ug/L、50 ug/L、100 ug/L的IL-18孵育24小时;10umol/L、30umol/L的PDTC预处理HUVECs,再用100ug/L的IL-18刺激24小时;预先用10umol/ml、100umol/ml的辛伐他汀预处理HUVECs,再用100ng/L的IL-18刺激24小时;100 ug/L的IL-18刺激HUVECs 24小时后,用1umg/L、5ug/L的FKN中和抗体作用3小时。应用Transwell装置观察FKN对THP-1细胞的趋化效应;
(6)HUVECs与0ug/L、25 ug/L、50 ug/L、100 ug/L的IL-18孵育24小时;10umol/L、30umol/L的PDTC预处理HUVECs,再用100ug/L的IL-18刺激24小时;预先用10umol/ml、100umol/ml的辛伐他汀预处理HUVECs,再用100ng/L的IL-18刺激24小时;100 ug/L的IL-18刺激HUVECs 24小时后,用1umg/L、5ug/L的FKN中和抗体作用3小时。应用Flow chamber装置观察FKN在模拟生理血流环境下介导的HUVEC与THP-1细胞的粘附。
结果
(1)HUVECs与100ug/L的IL-18孵育1小时后,FKN表达无明显增加,与空白对照组相比p＞0.05;HUVECs与100ug/L的IL-18孵育6、12、24小时后,FKN的基因表达明显增加,与空白对照组比较p＜0.01;
(2)HUVECs与5ug/L的IL-18孵育24小时后,FKN表达量无明显增加,与空白对照组相比p＞0.05;HUVECs与25 ug/L、50 ug/L、100 ug/L的IL-18孵育24小时后,FKN的基因表达明显增加,与空白对照组比较p＜0.01;
(3)用10umol/L、30umol/L的PDTC预处理HUVEC后,再加入100ug/L的IL-18孵育24小时,FKN表达量明显减少,与未经PDTC处理的单纯100ug/L IL-18刺激组比较p＜0.01;
(4)用1 umol/L的辛伐他汀预处理HUVECs后,再加入100ug/L的IL-18孵育24小时,FKN表达量无明显变化,与单纯100ug/L IL-18刺激组比较p＞0.05;用10umol/L、100umol/L辛伐他汀预处理HUVEC后,再加入100ug/L的IL-18孵育24小时,FKN表达量明显减少,与未经辛伐他汀处理的单纯100ug/L IL-18刺激组比较p＜0.01。
(5)成功使用Tranwell装置进行了体外趋化试验;FKN能够趋化静息的THP-1细胞;
(6)不同浓度IL-18上调FKN表达后,对THP-1细胞的趋化效应明显增强,与对照组比较p＜0.01;PDTC、辛伐他汀预处理HUVEC后,该趋化效应明显减弱,与单纯IL-18刺激组相比p＜0.01;FKN中和抗体能够抑制FKN介导的趋化作用,与单纯IL-18刺激组相比p＜0.01。
(7)成功应用Flow chamber在体外模拟了人体生理状态的血液循环条件进行粘附实验;使用EDTA阻断其他黏附分子的参与后,FKN以非钙离子依赖的方式介导了HUVECs与单核细胞THP-1的粘附;
(8)不同浓度IL-18上调FKN表达后,THP-1细胞与HUVEC的粘附明显增加,与对照组比较p＜0.01;PDTC预处理HUVEC后,该粘附效应明显减弱,与单纯IL-18刺激组相比p＜0.01。FKN中和抗体能够抑制FKN介导的粘附作用,与单纯IL-18刺激组相比p＜0.01。10umol/ml的辛伐他汀预处理HUVEC后,未能明显抑制FKN介导的粘附反应,与单纯IL-18刺激组相比p＞0.05。100umol/ml的辛伐他汀能够明显抑制该粘附效应,与单纯IL-18刺激组相比p＜0.01。
结论
(1)IL-18能够呈浓度、时间依赖性上调FKN的基因表达。这种诱导作用与NF-KB信号转导途径有关;
(2)FKN能够趋化静息THP-1细胞,IL-18能够增加THP-1细胞的迁移;
(3)在模拟生理血液循环的条件下,FKN能够介导HUVECs与静息THP-1细胞的粘附,IL-18能够增强该粘附反应;
(4)辛伐他汀能够抑制IL-18诱导HUVECs上调表达FKNmRNA,抑制FKN介导的趋化及粘附作用。
Background
Fractalkine(FKN) is a membrane-tethered chemokine that functions as chemokines and adhesion molecules to capture and induce firm adhesion of a subset of leukocytes in a selectin- and integrin -independent manner.Soluble FKN can be released,presumably by proteolysis at a membrane-proximal dibasic cleavage site(Thr-Arg- Arg-Gln),and exhibits an efficient chemotactic activity for monocytes.The novel structure and functions of FKN suggest that it may play a key role in the multistep process of leukocyte trafficking,while raising several issues. Chronic inflammation is one of the mechanism of Atherosclerosis (AS).The migration of leukocyte through intima is an essential biological phenomena of inflammation.Monocytes are important cells for forming the foam cells.The primary step of this is to migrate through intima too.The molecular control of these essential trafficking events requires two broad classes of molecules:various cell adhesion molecules,as well as leukocyte chemotactic factors,the chemokine superfamily.Now we have increasingly more evidence that FKN participate in the formation and development of atherosclerosis(AS).
In recent years,increasing evidences has emerged from experimental and epidemiological data that interleukin- 18(IL- 18),a pro-inflammatory cytokinee involved in both innate and acquired immune responses,plays a key role in the inflammatory response that contributes to AS.Baseline circulating IL-18 levels were strongly predictive of future cardiovascular disease.Most past studies suggest that IL-18 function mainly through interferon-γ(IFN -γ),and could not intervene AS without IFN-γ.Recent studies make it clear that IL-18 could also mediate several reactions in a IFN -γindependent manner.Banding of IL-18 and IL-18 receptor enhances the secretion of IL-6、IL-8、ICAM-1 and MMPs.However,it remains unclear whether IL-18 up-regulate the expression of FKN,and participate AS through the chemotactic and adhesive function of FKN.
Simvastatin is the 3-hydroxy-3-methylglutanyl coenzyme A(HMG-CoA) reductase inhibitor lipid-lowering agents synthesized from degradation products of aspergillus terreus.It has been used as one of the important medicine for coronary heart diseases.Besides lipid-lowering function,Simvastatin could protect endothelial cells,improve myocardial ischemia,anti-inflammatory anti-thrombosis and stabilize atherosclerotic plaques.However,it is still unclear whether Simvastatin exert its role through effect the expression and chemotactic,adhesive function of FKN.
Objective
(1)To observe the expression of FKN induced by IL-18 in HUVECs, and to investigate its signal pathway.
(2)Using Transwell to observe the chemotaxis of FKN and the effect of IL- 18 on monocyts migration;
(3)Using in vitro Flow chamber mimic the vivo fluid dynamic environment to observe the adhesion between HUVECs and THP-lcells mediated by FKN and the effect of IL-18;
(4)To investigate the effect of Simvastatine on expression of Fractalk -ine upregulated by IL-18,and the interventional effect on chemotaxis, adhesive function of FKN.
Methods
(1) HUVECs were cultured and treated with IL-18 of concentrations 100μg/L for 0,1,6,12,24 hours.FKN mRNA expressions were determined by semi-quantitative reverse-transcription polymerase chain reaction(RT-PCR).
(2) HUVECs were cultured and treated with IL-18 of 4 different concentrations(5μg/L,25μg/L,50μg/L,and 100μg/L) for 24 hours.We determined mRNA expressions of FKN by semi-quantitative reverse-transcription polymerase chain reaction(RT-PCR).
(3) Pretreated HUVECs with PDTC(A specific inhibitor of NF-KB) of 2 different concentrations(10umol/L,30umol/L),then cells were treated with IL-18(100ug/L) for 24 hours,mRNA expressions of FKN were determined by semi-quantitative RT-PCR.
(4)Pretreated HUVECs with Simvastatine of 3 different concentrations (1 umol/L,10umol/L,100umol/L),then cells were treated with IL- 18 (100ug/L) for 24 hours.FKN mRNA expressions were determined by semi-quantitative RT-PCR.
(5) HUVECs were treated as above 1,3,4 method.The other HUVECs were cultured and treated with IL- 18 of 100 ug/L for 24 hours, then cells were treated with neutralizing antibody of FKN(1 ug/L,5ug/L) for 2 hours.The migration of THP-1 cells mediated by FKN was odserved by Transwell.
(6) HUVECs were treated as above 1,3,4 method.The other HUVECs were cultured and treated with IL- 18 of 100 ug/L for 24 hours, then cells were treated with neutralizing antibody of FKN(1ug/L,5ug/L) for 2 hours.The adhesion of HUVECs and THP-1 cells mediated FKN was odserved by In vitro Flow chamber assay.
Results
(1) HUVECs cultured and incubated with 100ug/L IL- 18 for 1 hour resulted in no difference of FKNmRNA expression as compared with control group(p＞0.05);HUVECs were cultured and incubated with IL-18 of concentrations 100μg/L for 6,12,24 hours resulted in upregulated expression of FKNmRNA,as compared with control group (p＜0.01);
(2) HUVECs cultured and incubated with 5ug/L IL-18 for 24 hours resulted in no difference of FKNmRNA expression,as compared with control group(p＞0.05);HUVECs were cultured and incubated with IL-18 of concentrations 25,50,100μg/L for 24 hours resulted in upregulated expression of FKNmRNA,as compared with control group(p＜0.01);
(3) Pretreated HUVECs with PDTC of 10umol/L,30umol/L and then incubated with IL-18(100ug/L) for 24h resulted in downregulated expression of FKN mRNA,as compared with the pure IL-18(100ug/L) group(p＜0.01);
(4) Pretreated HUVECs with Simvastatin of 1umol/L and then incubated with IL-18(100ug/L) for 24h resulted in no difference of FKNmRNA expression,as compared with the pure IL-18(100ug/L) group (p＞0.05);Pretreated HUVECs with Simvastatin of 10umol/L and 100umol/L and then incubated with IL-18(100ug/L) for 24h resulted in down-regulated expression of FKN mRNA,as compared with the pure IL-18(100ug/L) group(p＜0.01).
(5)The chemotactic assay was successful by using Transwell,FKN could chemotaxis the resting THP-1 cells;
(6) After up-regulated FKN mRNA expression induced by IL-18 with different concentrations,the chemotactic effect of FKN to THP-1 cells were enhanced significantly,consistent to the expression of FKN mRNA.The chemotactic effect were inhibited if HUVECs pretreated with Simvastatin or PDTC,or treated with neutralizing antibody,as compared with the pure IL-18(100ug/L) group(p＜0.01)
(7)Using in vitro flow chamber mimic the vivo fluid environment secessfully,FKN could mediate the adhesion in a Ca~(2+) independent maner;
(8) After up-regulated FKN mRNA expression induced by IL- 18,the adhesion mediated by FKN was enhanced significantly,as compared with control group(p＜0.01).The adhesion were inhibited after HUVECs pretreated with PDTC,or treated with neutralizing antibody,as compared with pure IL-18(100ug/L) group(p＜0.01).Simvastatin with 10umol/ml concentration did not inhibit the adhesion,as compared with the pure IL-18(100ug/L) group(p＞0.05).Simvastatin with concentration of 100umol/L inhibated the adhesion,as compared with the pure IL- 18(100ug/L) group(p＜0.01).
Conclusions
(1) IL-18 could up-regulate the expression of FKN mRNA in a dose-and time-dependent manner,and this effect might be related to NF-KB.
(2) IL-18 could enhance the chemotactic and adhesive effect of HUVECs to THP-1 cells significantly by up- regulation of FKN.
(3) Simvastatin could down-regulated the expression of FKN mRNA induced by IL-18,and inhabit the chemotactic and adhesion.
引文
1.Ross R.Atherosclerosis--an inflammatory disease[J].N Engl J Med.1999,340(2):115-126
2.Shah P K.Plaque disruption and thrombosis.Potential role of inflammation and infection[J].Cardiol Clin,1999,17(2):271-281
3.Glass CK,Witztum JL.Atherosclerosis.the road ahead[J].Cell.2001,104(4):503-516
4.Laing KJ,Secombes CJ.Chemokines[J].Dev Comp Immunol.2004,28(5):443-460
5.Bazan JF,Bacon KB,Hardiman G,et al.A new class of membrane-bound chemokine with a CX3C motif[J].Nature.1997,385(6617):640-644
6.Foussat A,Coulomb-L'Hermine A,Gosling J.Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human.Eur J Immunol.2000,30(1):87-97.
7.Moon SO,Kim W,Sung MJ,et al.Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells[J].Mol Pharmacol.2006 70(1):112-119
8.Ahn SY,Cho CH,Park KG,et al.Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression[J].Am J Pathol.2004164(5):1663-1672
9.Sung MJ,Kim W,Ahn SY,et al.Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression[J].Circ Res.2005,97(9):880-890
10.Boisvert WA.Modulation of atherogenesis by chemokines[J].Trends Cardiovasc Med.2004,14(4):161-169
11.Lutgens E, Faber B, Schapira K, et al.Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody[J].Circulation.2005,111(25):3443-3452.
12.Schulz C, Schafer A, Stolla M, et al.Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets[J].Circulation,2007,116 (7):764-773.
13.Loosdregt J, van Oosterhout MF, Bruggink AH, et al.The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response [J].Circulation. 2006,114(15):1599-1607.
14.Lesnik P,Haskell CA,Charo JF,et al.Reveals a role for Decreased atherosclerosis in CX3CR1-/- pucefractalkine inrogenesis[J].J Clin Invest.2003,111:333-340.
15.Combadiere C,Potteaux S,Gao JL,et al.Decreased atherosclerotic lesion formation in CX3CRl/apolipoprotein E double knockout mice[J].Circulation. 2003,107(7):1009-1016.
16.Saederup N,Chan L,Lira SA,Charo IF,et al. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice:evidence for independent chemokine functions in atherogenesis [J].Circulation. 2008,117(13):1642-8
17.Philippe L,Christopher A,Haskell T,et al.Decreased atherosclerosis in CX3CR1~(-/-) mice reveals a role for fractalkine in atherogenesis[J].J Clin Invest. 2003,111(3):333-340.
18.McDermott DH,Halcox JP,Schenke WH,et al.Association between polymer-phism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis [J].Circ Res. 2001,89(5):401-407
19.McDermott DH,Fong AM,Yang Q,et al.Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans [J]. J Clin Invest. 2003,111(8):1241-1250.
20. Moatti D,Faure S,Fumeron F,et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease[J].Blood. 2001,97(7): 1925-1928
21. Damas JK,BoulIier A,Waehre T,et al.Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy[J].Arterioscler Thromb Vasc Biol. 2005, 25(12): 2567-2572
22. Sahar S,Dwarakanath R S,Reddy M A,et al.Angiotensin Ⅱ enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells:a novel crosstalk in the pathogenesis of atherosclerosis[J].Circ Res,2005,96:1064 -1071.
23. MitsuokaH, KumeN, Hayashida K, et al.Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1(sLOX-1)[J].Atherosclerosis.2009, 202(1):176-182.
24. Brown MS , Goldstein JL. Mad bet for Rab. Nature , 1993 ,366 :14-15.
25. Sparrow C P,Burton C A,Hernandez M,et al.Simvastatin has antiinfiammatory and antiatherosclerotic activities independent of plasma cholesterol lowering [J].Arterioscler Thromb Vasc Biol,2001,21(4) :115 - 121.
26. Tenger C,Sundborger A,Jawien J,et al.IL-18 accelerate atherosclerosis accompanied by elevation Of IFN-gamma and CXCL16 expression indepen- dently of T cells [J] . Arterioscler Thromb Vasc Biol ,2005,25 :791 - 796.
27. Mallat Z,Corbaz A,Scoazec A,et al.Interleukin-18/ interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability[J].Circ Res,2001,89:e41-e45.
28. Blankenberg S,Luc G,Ducimetiere P, et al. Interleukin-18 and the risk of coronary heart disease in European men : the prospective epidemiological study of myocardial Infarction ( PRIME) [J].Circulation ,2003,108(9):2453 - 2459.
29. Zernecke A,Weber K,Weber C,et al.Combined modulation of the mesangial machinery for monocyte recruitment by inhibition of NF-kappaB [J]. Am J Physiol Cell Physiol,2001,281(6):C1881-1888.
30.Garcia GE, Xia Y, Chen S, et al. NF-cappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1 beta,TNF-apha,and LPS[J].J Leuk oc Biol. 2000,67(4):577-584.
31.Kojima H,Takeuchi M,Ohta T.Interleukin-18 activates the IRAK-TRAF6 pathway in mouse EL-4 cells. Biochem Biophys Res Commun. 1998,244(1): 183-186.
32.Rezaie-Majd A, Praqer GW, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients[J].Arterioscler Thromb Vasc Biol, 2003, 23(3):397-403
33.Sampson MJ,Davies IR,Brasch S,et al.Increased expression of a scavenger receptor (CD36) in monocytes from subjects with type 2 diabetes[J].Atherosclerosis, 2003,167(6):129-134.
34.Gfifm E,Re A,Hamel N,et al.A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation[J].Nat Med,2000, 7(8):840-846.
35.Ortego M,Gomez2Hemandez A,Vidal C,et al.HMG-CoA reductase inhibitors reduce I kappaB kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells[J]. J Cardiovasc Pharmacol,2005,45(8):468-475.
1.Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane bound chemokine with a CX3C motif [J].Nature 1997,385 (6617):640-644 .
2.Werb Z,Yan Y,et al.A cellular striptease act[J].Science,1998,282(5392): 1279-80.
3.Pan Y, Lloyd C, Zhou H,et al. Neurotactin, a membrane anchored chemokine upregulated in brain inflammation [J]. Nature. 1997,387(6633):611-617
4.Bursill CA,Channon KM,Greaves DR,et al.The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics [J]. Curr Opin Lipidol. 2004,15(2):145-149.
5.Loosdregt J,van Oosterhout MF,Bruggink AH,et al.The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response [J]. Circulation. 2006,114(15):1599-1607.
6.Boisvert WA.Modulation of atherogenesis by chemokines[J].Trends Cardiovasc Med. 2004,14(4): 161-169
7.Lutgens E, Faber B, Schapira K,et al.Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody[J].Circulation.2005,111(25):3443-3452.
8.Okamura H,Nagata K,Komatsu T,et al.A novel costimulatorv factor for gamma interferon induction found in the livers of mice causes endotoxic shock [T]. Infect Immun,1995,63(10):3966-3972
9.Nooijer R,vonder Thusen JH,Verkleij CJ,et al.Over expression of IL-18 decreases intimal collagen contentand promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice[J].Arterioscler Thromb Vasc Biol,2004,24(12):2313-2319.
10.Tenger C,Sundborger A,Jawien J,et al.IL-18 accelerate atherosclerosis accompanied by elevation Of IFN-gamma and CXCL16 expression independently of T cells[J].Arterioscler Thromb Vasc Biol 2005,25:791-796.
11.Mallat Z,Corbaz A,Scoazec A,et al. Interleukin-18/ interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability[J].Circ Res,2001,89 :e41 -e45.
12.Whitman SC,Ravisankar P,Daugherty A,et al.Interleukin-18 enhances atherosclerosis in apolipoprotein E~(-/-) Mice through release of interferon- γ [J].Circ Res,2002,90 (2 ) :E34-E38.
13.Blankenbergs S, Luc G,Ducimetiere P,et al.Interleukin-18 and the risk of coronary heart disease in European men : the prospective epidemiological study of myocardial Infarction ( PRIME) [J].Circulation ,2003,108(11):2453 - 2459.
14.Hulthe J,McPheat W,Samneg(?)rd A,et al.Plasma interleukin(IL)-l 8 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6[J]. Atheros-clerosis.2006,188(2):450-454.
15.Samantha Paoletti, Vibor Petkovic, Silvia Sebastiani, M.A rich chemokine environment strongly enhances leukocyte migration and activities[J].Blood,2005, 105(6): 3405-3412.
16.Nomura S,Tandon NN,Nakamura T.High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells[J].Atherosclerosis.2001.158(2):277-287.
17.Berdnikovs S,Abdala-Valencia H,McCary C.Isoforms of vitamin E have opposing immunoregulatory functions during inflammation by regulating leukocyte recruitment[J].J Immunol. 2009,82(7):4395-4405.
18.Ruotsalainen E,Vauhkonen I,Salmenniemi U.Markers of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects[J]. Atherosclerosis. 2008,197(l):271-277.
19.Saremi A, Robert J. Anderson, et al.Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis, 2009,203(2): 610-614
20.Aramesh Saremi, Robert J. Anderson, Rosaria Piga, Yuji Naito, Satoshi Kokura. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells.Atherosclerosis, 2007,193(2),328-334
21.George E,Christodoulakos,Irene V.Lambrinoudaki,.Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene.Atherosclerosis, 2007, 193(1):142-150
22.Blanco-Colio LB, Mu(?)oz-Garc(?)a B, Mart(?)n-Ventura J L.Ethanol beverages containing polyphenols decrease nuclear factor kappa-B activation in mononuclear cells and circulating MCP-1 concentrations in healthy volunteers during a fat-enriched dietAtherosclerosis, 2007, 192(2):335-341
23.Tiret L, Godefroy T, Lubos E,et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease [J].Circulation.2005,112(5):643-650.
24.Bis JC,Heckbert SR,Smith NL,et al.Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke[J].Atherosclerosis.2008,198(1):166-173.
25.张承俊,朱兴雷等。辛伐他汀对肿瘤坏死因子α诱导的人脐静脉内皮细胞基质金属蛋白酶9表达的影响。中国动脉硬化杂志,2006年,第一期,50-52
1.Umehara H,Bloom ET,Okazaki T,et al.Fractalkine in vascular biology:from basic research to clinical disease[J].Arterioscler Thromb Vasc Biol.2004,24(1)3440.
2.Hoover DM,Mizoue LS,Handel TM,et al.The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement[J].J Biol Chem.2000,275(30):23187-23193.
3.Nomiyama H,Imai T,Kusuda J,et al.Human chemokines fractalkine (SCYD1),MDC(SCYA22) and TARC(SCYA17) are clustered on chromosome 16q13[J].Cytogenet Cell Genet.1998;81(1):10-11.
4.Fong AM,Robinson LA,Steeber DA,et al.Fractalkine and CX3CR 1mediate a novel mechanism of leukocyte capture,firm adhesion,and activation under physiologic flow[J].J Exp Med.1998,188(8):1413-1419.
5.Imai T,Hieshima K,Haskell C,et al.Identification and molecular characterization of fractalkine receptor CX3CR1,which mediates both leukocyte migration and adhesion[J].Cell.1997,91(11):521-530
6.Yoneda O,Imai T,Goda S,et al.Fractalkine-mediated endothelial cell injury by NK cells[J].J Immunol.2000,164(8):405540-405562
7.Goda S,Imai T,Yoshie O,et al.CX3C-chemokine,fractalkine enhanced adhesion of THP-1 cells to endothelial cells through integrine dependent and independent mechanisms[J].J Immunol.2000,164(8):4313-4320:
8.Loosdregt J, van Oosterhout MF, Bruggink AH,et al.The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response [J]. Circulation. 2006,114(15):1599-1607.
9.Damas JK, Boullier A, Waehre T, et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy[J].Arterioscler Thromb Vasc Biol. 2005, 25(12): 2567-2572
10.Moon SO, Kim W, Sung MJ, et al. Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells[J]. Mol Pharmacol. 2006,70(1):112-119
11.Ahn SY, Cho CH, Park KG, et al. Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression[J].2004,164(5):1663-1672
12.Sung MJ, Kim W, Ahn SY, et al. Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression[J].Circ Res. 2005,97(9): 880-890
13.McDermott DH,Halcox JP,Schenke WH,et al.Association between polymer-phism in the chemokine receptor CX3CR 1 and coronary vascular endothelial dysfunction and atherosclerosis [J]. Circ Res. 2001,89(5):401-407
14.McDermott DH,Fong AM,Yang Q,et al.Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans [J]. J Clin Invest. 2003,111(8):1241-1250.
15.Moatti D,Faure S,Fumeron F,et al.Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease[J].Blood. 2001,97(7): 1925-1928
16.White PR.Versatile perfusion chamber for living cells and organs[J].Science. 1966,152(730):1758-1760
17.Ditenfass,Osman P.D,Jedrejczyk H.First haemorheological experiment on NASA space shuttle 'Discovery'sts 51-C:Aggregation of red cells[J].Clinical Hemorheology. 1985,.5(5)917-936.
18.Lawrence MB,McIntire LV,Eskin S.G,et al.Effect of flow on polymorpho-nuclear leukocyte/endothelial cell adhesion[J].Blood, 1987,70(6),1284- 1290.
19.Gopalan P. K,Jones DA,McIntire LV,Smith CW.Cell adhesion under hydrodynamic flow conditions, in Current Protocols in Immunology.Wiley, New York. pp. 1996.7.29.1-7.29.23
20.Campbell JJ, Hedrick J, Zlotni kA, et al. Chemokines and the arrest of lymphocytes rolling under flow conditions [J]. Science , 1998 , 279(5349):381-384.
21.Badimon L,Chesebro JH,Badimon JJ.Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation. 1992, 86(6):Ⅲ74-85.
22.von Hundelshausen P, Weber KS, Huo Y.RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation. 2001,103(13):1718-1720.
23.Gill V,Doig C,Knight D.Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin[J].Circulation.2005,112(13): 2031-2039.
24.Yamaguchi J,Kusano KF,Masuo O.Stromal cell-derived factor-1 effects on ex-vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization[J].Circulation.2003,107(9):1322-1328
25.Kaufmann BA, Sanders JM, Davis C.Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1 [J].Circulation. 2007,116(3):276-284
26.Luscinskas, FW,Ding H,Lichtman A.H.P-selectin and VCAM-1 mediate rolling and arrest of CD4+ T-lymphocytes on TNF-activated vascular endothelium under flow[J].Exp.Med. 1995, 181(6), 1179-1186.
27.Kadono T,Venturi GM,Steeber DA.Leukocyte rolling velocities and migration are optimized by cooperative L-selectin and intercellular adhesion molecule-1 functions.J Immunol. 2002,169(8):4542-4250.
28.Bengtson P,Lundblad A,Larson GPolymorphonuclear leukocytes from individuals carrying the G329A mutation in the alpha 1,3-fucosyltransferase Ⅶ gene (FUT7) roll on E- and P-selectins..J Immunol. 2002,169(7):3940-3946.
29.Ulfman LH, Joosten DP, van der Linden JA .IL-8 induces a transient arrest of rolling eosinophils on human endothelial cells.J Immunol. 2001,166(1):588-595.
30.Fitzhugh DJ, Naik S, Caughman SW, Hwang ST.Cutting edge:C-C chemokine receptor 6 is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells under physiologic flow conditions in vitro[J].J Immunol. 2000,165(12):6677-6681.
1.Bazan JF,Bacon KB,Hardiman G,et al.A new class of membrane bound chemokine with a CX3C motif[J].Nature 1997,385(6617):640-644.
2.Werb Z,Yan Y,et al.A cellular striptease act[J].Science.1998,282(5392):1279-1280.
3.Pan Y,Lloyd C,Zhou H,et al.Neurotactin,a membrane-anchored chemokine upregulated in brain inflammation[J].Nature.1997,387(6633):611-617
4.Hoover DM,Mizoue LS,Handel TM,et al.The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement.J Biol Chem.2000 Jul 28;275(30):23187-23193.
5.Nomiyama H,Imai T,Kusuda J,et al.Human chemokines fractalkine(SCYD 1),MDC(SCYA22) and TARC(SCYA17) are clustered on chromosome 16q13[J]. Cytogenet Cell Genet. 1998;81(1):10-11.
6.Nishiyori A,Minami M,Ohtani Y,et al. Localization of fractalkine and CX3CRlmRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia FEBS Lett [J]. 1998,429(2):167-172.
7.Harrison JK, Jiang Y, Chen S,et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1 expressing microglia [J]. ProcNatlAcad Sci U S A. 1998,95(18): 10896-10901
8.Foussat A, Coulomb-L'Hermine A, Gosling J. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human.Eur J Immunol. 2000,30(1):87-97.
9.Garcia GE,Xia Y,Chen S,et al. NF-cappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1 beta,TNF-apha,and LPS [J]. J Leuk oc Biol. 2000,67(4):577-584.
10.Cambien B, Pomeranz M, Schmid Antomarchi H,et al. Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion [J].Blood. 2001,97(7):2031-2027
11.Kansra V,Groves C,Gutierrezamos JC,et al.Phosphatidylinositol cinase depen- dent extracellular calcium influx is essential for CX(3)CR1 mediated activation of the mitogen activated protein kinase cascade[J].J Biol Chem.2001,276 (34):318-331.
12.Campbell JJ,QinS,BaconKB,et al.Biology of chemokin and classical chemoattractant receptors:differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells[J] J Cell Biol,1996,134(1):255-266.
13.Combadiere C,SalzwedelK,Smith ED,et al.Identification of CX3CR1 :A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor forHIV-1 [J].J Biol Chem,1998,273(37):23799-23804.
14.Combadiere C,Ahuja SK,Murphy PM,et al. Cloning,chromosomal localization,and RNA expression of a human beta chemokine receptor- likegene[J].DNA Cell Biol,1995,14 (8): 673 -680.
15.Baggiolini M,Dewald B,Moser B,et al.Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines [J] Adv Immunol,1994,55:97-179.
16.Baggiolini M,Dewald B,Moser B,et al.Human chemokines An update[J]. Annu Rev Immunol, 1997,15:675-70
17.Mizoue LS,Bazan JF,Johnson EC,et al.Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1 [J]. Biochemistry,1999,38(5):1402-1410
18.Garin A, Pellet P, Deterre P,et al. Cloning and functional characterization of the human fractalkine receptor promoter regions[J].Biochem J.2002,368 (3):753-760
19.Umehara H, Bloom ET, Okazaki T,et al. Fractalkine in vascular biology: from basic research to clinical disease[J].Arterioscler Thromb Vase Biol. 2004 ,24(1) 3440-3445
20.Harrison JK, Fong AM, Swain PA,et al. Mutational analysis of the fractalkinechemokine domain. Basic amino acid residues differentially contribute to CX3CR1 binding,signaling,and cell adhesion[J] J Biol Chem.2001,276 (24):216-232
21.Fong AM, Robinson LA, Steeber DA,et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture,firm adhesion,and activation under physiologic flow [J]. J Exp Med. 1998,188(8):14139-14145
22.Imai T,Hieshima K,Haskell C,et al.Identification and molecular characterization of fractalkine receptor CX3CR1,which mediates both leukocyte migration and adhesion [J]. Cell. 1997,91(4):521-530
23.Fong AM, Erickson HP, Zachariah JP,et al. Ultrastructure and function of the fractalkine mucin domain in CX(3)C chemokine domain presentation [J]. J Biol Chem. 2000,275(6):3781-3786.
24.Yoneda O, Imai T, Goda S,et al. Fractalkine-mediated endothelial cell injury by NK cells [J]. J Immunol. 2000,164(8):4055-4062
25.Goda S, Imai T, Yoshie O,et al. CX3C-chemokine, fractalkine enhanced adhesion of THP-1 cells to endothelial cells through integrine dependent and independent mechanisms [J]. J Immunol. 2000 ,164(8):4313-4320
26.Bursill CA,Channon KM,Greaves DR,et al.The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics[J]. Curr Opin Lipidol. 2004,15(2):145-149.
27.Loosdregt J, van Oosterhout MF, Bruggink AH,et al.The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response [J]. Circulation. 2006,114(15):1599-1607.
28.Boisvert WA. Modulation of atherogenesis by chemokines[J].Trends Cardio-vasc Med. 2004,14(4): 161-169
29.Lutgens E,Faber B,Schapira K,et al.Gene profiling in atherosclerosis reveals a key role for small inducible cytokines:validation using a novel monocyte chemoattractant protein monoclonal antibody[J].Circulation.2005,111(25):3443-3452.
30.Schulz C,Schafer A,Stolla M,et al.Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets[J].Circulation.2007,116 (7):764-773.
31.Lesnik P, Haskell CA, Charo JF,et al. Reveals a role for Decreased atherosclerosis in CX3CR1~(-/-) pucefractalkine inrogenesis[J].J Clin Invest.2003, 1119 (9):333-340.
32.Combadiere C, Potteaux S, Gao JL,etal .Decreased atherosclerotic lesion formation in CX3CRl/apolipoprotein E double knockout mice [J]. Circulation. 2003 ,107(7):1009-1016.
33.Saederup N,Chan L,Lira SA,Charo IF,et al. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2~(-/-) mice: evidence for independent chemokine functions in atherogenesis [J].Circulation. 2008,117(13):1642-1648.
34.Philippe L,Christopher A,Haskell T et al.Decreased atherosclerosis in CX3CR1~(-/-) mice reveals a role for fractalkine in atherogenesis [J]. J Clin Invest. 2003 ,111(3): 333-340.
35.McDermott DH,Halcox JP,Schenke WH,et al.Association between polymorphism in the chemokine receptor CX3CR 1 and coronary vascular endothelial dysfunction and atherosclerosis [J]. Circ Res. 2001,89(5):401-407
36.McDermott DH,Fong AM,Yang Q,et al. Chemokine receptor mutant CX3CR1 -M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans [J]. J Clin Invest. 2003,111(8):1241-1250.
37.Moatti D,Faure S,Fumeron F,et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease [J]. Blood. 2001,97(7): 1925-1928
38.Okamura H,Nagata K,Komatsu T,et al. A novel costimulatorv factor for gamma interferon induction found in the livers of mice causes endotoxic shock [J] . Infect Immun,1995,63(10):3966-3972
39.Kohno K, Kataok A ,Ohtsuki T , et al.IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12 [J].J Immunol ,1997,158(7):1541-1550.
40.Lebel-Binay S,Berger A,Zinzindohoue F,et al.Interleukin-18:biological properties and clinical implications [J].Eur Cytokine Netw,2000,11(1): 15-21
41.KohnoK,KurimotoM,et al.hiterleukinl8,a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both [JJ.Clin Immunol Immunopathol,1998,86(1):11-18
42.Berclaz PY,Shibata Y,Whitsett JA,et al. GM-CSF,viaPU.1,regulates alveolar macrophage Fcgamma R-mediated phagocytosis and the IL-18/IFN-gamma-mediated molecular connection between innate and adaptive immunity in the lung [J].Blood, 2002,100(12):4193-4199
43.Heath VL,Kurata H,Lee HJ,et al.Checkpoints in the regulation of T helper 1 responses [J].Curr Top Microbiol Immunol,2002,266(6):23-27
44.Mallat Z,Corbaz A,Scoazec A,et al.Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability[J].Circulation,2001,104(7): 1598-1603.
45.Tenger C,Sundborger A,Jawien J,et al.IL-18 accelerate atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells[J].Arterioscler Thromb Vasc Biol 2005,25:791-796.
46.Mallat Z,Corbaz A,Scoazec A,et al.Interleukin-18/ interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability[J].Circ Res,2001,89:e41-e45.
47.Maffia P,Grassia G,Di Meglio P,et al.Neutralization of interleukin-18 inhibits neointimal formation in a rat model of vascular injury[J].Circulation.2006,114 (5):430-437
48.Kretowski A,Kinalska I,et al.Serum levels of interleukin-18 a potential marker of cardiovascular death-could be determined by genetic predisposition[J]. Circulation. 2003,107(22):e206-e207
49.Tiret L,Godefroy T,Lubos E,et al.Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease [J].Circulation. 2005,112(5):643-650.
50.Bis JC,Heckbert SR,Smith NL,et al.Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke[J].Atherosclerosis. 2008,198(1):166-173.
51.Blankenberg S,Tiret L ,Bickel C,et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina [J].Circulation,2002,106(8):24-30.
52.Blankenberg S,Luc G,Ducimetiere P,et al.Interleukin-18 and the risk of coronary heart disease in European men:the prospective epidemiological study of myocarndial Infarction (PRIME) [J].Circulation,2003,108(5):2453-2459.
53.Chalikias GK,Tziakas DN,Kaski JC,et al.Interleukin-18: interleukin-10 ratio and in hospital adverse events in patients with acute coronary syndrome[J]. Atherosclerosis. 2005,182(1):135-143.
54.Tziakas DN,Chalikias GK,Kaski JC,et al.Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients:a factor ana- lysis approach[J]. Atherosclerosis. 2007,193(l):196-203.
55.Hulthe J, McPheat W, Samneg(?)rd A,et al.Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6[J]. Atherosclerosis. 2006,188(2):450-454.
56.Samneg(?)rd A, Hulthe J, Silveira A,et al.Gender specific associations between matrix met alloproteinases and inflammatory markers in post myocardial infarction patients[J].Atherosclerosis. 2009,202(2):550-556.
57.Hernesniemi JA,Karhunen PJ,Rontu R,et al.Interleukin-18 promoter polymor-phism associates with the occurrence of sudden cardiac death among Caucasian males:the Helsinki Sudden Death Study [J].Atherosclerosis.2008,196(2): 643-649.
58.Gupta S,Pablo AM Jiang X,et al. IFN-gamma potentiates atherosclerosis in Apo E knock out mice[J].J Clin Invest,1997,99(7):2752-2761.
59.Yoshimoto T,Takeda K,Tanaka T,et al.IL-12 up-regulates IL-18 receptor expression on T cells Thl cells and B cells.syn-ergism with IL-18 for IFN- γ production[J].J Immunol, 1998,161(7):3400-3407.
60.Whitman SC,Ravisankar P,Daugherty A,et al.Interleukin-18 enhances atherosclerosis in apolipoprotein E~(-/-) Mice through release of interferon- Y [J].Circ Res,2002, 90 (2) :E34-E38.
61.Elhage R,Jawien J,Rudling M,et al.Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice[J].CardiovascRes,2003,59(1):234-240.
62.de Nooijer R,vonder Thusen JH,Verkleij CJ,et al.Over expression of IL-18 decreases intimal collagen contentand promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice[J].Arterioscler Thromb Vasc Biol,2004,24(12):2313-2319.
63.Sa har S,Dwarakanath RS,Reddy MA,et al.Angiotensin Ⅱ enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells:a novel crosstalk in the pathogenesis of atherosclerosis[J].Circ Res,2005,96(4): 1064-1071.
64.Mitsuoka H, Kume N, Hayashida K,et al.Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1 (sLOX-1) [J]. Atherosclerosis. 2009,202(1):176-182.
2.Shah P K.Plaque disruption and thrombosis.Potential role of inflammation and infection[J].Cardiol Clin,1999,17(2):271-281
3.Glass CK,Witztum JL.Atherosclerosis.the road ahead[J].Cell.2001,104(4):503-516
4.Laing KJ,Secombes CJ.Chemokines[J].Dev Comp Immunol.2004,28(5):443-460
5.Bazan JF,Bacon KB,Hardiman G,et al.A new class of membrane-bound chemokine with a CX3C motif[J].Nature.1997,385(6617):640-644
6.Foussat A,Coulomb-L'Hermine A,Gosling J.Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human.Eur J Immunol.2000,30(1):87-97.
7.Moon SO,Kim W,Sung MJ,et al.Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells[J].Mol Pharmacol.2006 70(1):112-119
8.Ahn SY,Cho CH,Park KG,et al.Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression[J].Am J Pathol.2004164(5):1663-1672
9.Sung MJ,Kim W,Ahn SY,et al.Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression[J].Circ Res.2005,97(9):880-890
10.Boisvert WA.Modulation of atherogenesis by chemokines[J].Trends Cardiovasc Med.2004,14(4):161-169
11.Lutgens E, Faber B, Schapira K, et al.Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody[J].Circulation.2005,111(25):3443-3452.
12.Schulz C, Schafer A, Stolla M, et al.Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets[J].Circulation,2007,116 (7):764-773.
13.Loosdregt J, van Oosterhout MF, Bruggink AH, et al.The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response [J].Circulation. 2006,114(15):1599-1607.
14.Lesnik P,Haskell CA,Charo JF,et al.Reveals a role for Decreased atherosclerosis in CX3CR1-/- pucefractalkine inrogenesis[J].J Clin Invest.2003,111:333-340.
15.Combadiere C,Potteaux S,Gao JL,et al.Decreased atherosclerotic lesion formation in CX3CRl/apolipoprotein E double knockout mice[J].Circulation. 2003,107(7):1009-1016.
16.Saederup N,Chan L,Lira SA,Charo IF,et al. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice:evidence for independent chemokine functions in atherogenesis [J].Circulation. 2008,117(13):1642-8
17.Philippe L,Christopher A,Haskell T,et al.Decreased atherosclerosis in CX3CR1~(-/-) mice reveals a role for fractalkine in atherogenesis[J].J Clin Invest. 2003,111(3):333-340.
18.McDermott DH,Halcox JP,Schenke WH,et al.Association between polymer-phism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis [J].Circ Res. 2001,89(5):401-407
19.McDermott DH,Fong AM,Yang Q,et al.Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans [J]. J Clin Invest. 2003,111(8):1241-1250.
20. Moatti D,Faure S,Fumeron F,et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease[J].Blood. 2001,97(7): 1925-1928
21. Damas JK,BoulIier A,Waehre T,et al.Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy[J].Arterioscler Thromb Vasc Biol. 2005, 25(12): 2567-2572
22. Sahar S,Dwarakanath R S,Reddy M A,et al.Angiotensin Ⅱ enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells:a novel crosstalk in the pathogenesis of atherosclerosis[J].Circ Res,2005,96:1064 -1071.
23. MitsuokaH, KumeN, Hayashida K, et al.Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1(sLOX-1)[J].Atherosclerosis.2009, 202(1):176-182.
24. Brown MS , Goldstein JL. Mad bet for Rab. Nature , 1993 ,366 :14-15.
25. Sparrow C P,Burton C A,Hernandez M,et al.Simvastatin has antiinfiammatory and antiatherosclerotic activities independent of plasma cholesterol lowering [J].Arterioscler Thromb Vasc Biol,2001,21(4) :115 - 121.
26. Tenger C,Sundborger A,Jawien J,et al.IL-18 accelerate atherosclerosis accompanied by elevation Of IFN-gamma and CXCL16 expression indepen- dently of T cells [J] . Arterioscler Thromb Vasc Biol ,2005,25 :791 - 796.
27. Mallat Z,Corbaz A,Scoazec A,et al.Interleukin-18/ interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability[J].Circ Res,2001,89:e41-e45.
28. Blankenberg S,Luc G,Ducimetiere P, et al. Interleukin-18 and the risk of coronary heart disease in European men : the prospective epidemiological study of myocardial Infarction ( PRIME) [J].Circulation ,2003,108(9):2453 - 2459.
29. Zernecke A,Weber K,Weber C,et al.Combined modulation of the mesangial machinery for monocyte recruitment by inhibition of NF-kappaB [J]. Am J Physiol Cell Physiol,2001,281(6):C1881-1888.
30.Garcia GE, Xia Y, Chen S, et al. NF-cappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1 beta,TNF-apha,and LPS[J].J Leuk oc Biol. 2000,67(4):577-584.
31.Kojima H,Takeuchi M,Ohta T.Interleukin-18 activates the IRAK-TRAF6 pathway in mouse EL-4 cells. Biochem Biophys Res Commun. 1998,244(1): 183-186.
32.Rezaie-Majd A, Praqer GW, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients[J].Arterioscler Thromb Vasc Biol, 2003, 23(3):397-403
33.Sampson MJ,Davies IR,Brasch S,et al.Increased expression of a scavenger receptor (CD36) in monocytes from subjects with type 2 diabetes[J].Atherosclerosis, 2003,167(6):129-134.
34.Gfifm E,Re A,Hamel N,et al.A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation[J].Nat Med,2000, 7(8):840-846.
35.Ortego M,Gomez2Hemandez A,Vidal C,et al.HMG-CoA reductase inhibitors reduce I kappaB kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells[J]. J Cardiovasc Pharmacol,2005,45(8):468-475.
1.Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane bound chemokine with a CX3C motif [J].Nature 1997,385 (6617):640-644 .
2.Werb Z,Yan Y,et al.A cellular striptease act[J].Science,1998,282(5392): 1279-80.
3.Pan Y, Lloyd C, Zhou H,et al. Neurotactin, a membrane anchored chemokine upregulated in brain inflammation [J]. Nature. 1997,387(6633):611-617
4.Bursill CA,Channon KM,Greaves DR,et al.The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics [J]. Curr Opin Lipidol. 2004,15(2):145-149.
5.Loosdregt J,van Oosterhout MF,Bruggink AH,et al.The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response [J]. Circulation. 2006,114(15):1599-1607.
6.Boisvert WA.Modulation of atherogenesis by chemokines[J].Trends Cardiovasc Med. 2004,14(4): 161-169
7.Lutgens E, Faber B, Schapira K,et al.Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody[J].Circulation.2005,111(25):3443-3452.
8.Okamura H,Nagata K,Komatsu T,et al.A novel costimulatorv factor for gamma interferon induction found in the livers of mice causes endotoxic shock [T]. Infect Immun,1995,63(10):3966-3972
9.Nooijer R,vonder Thusen JH,Verkleij CJ,et al.Over expression of IL-18 decreases intimal collagen contentand promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice[J].Arterioscler Thromb Vasc Biol,2004,24(12):2313-2319.
10.Tenger C,Sundborger A,Jawien J,et al.IL-18 accelerate atherosclerosis accompanied by elevation Of IFN-gamma and CXCL16 expression independently of T cells[J].Arterioscler Thromb Vasc Biol 2005,25:791-796.
11.Mallat Z,Corbaz A,Scoazec A,et al. Interleukin-18/ interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability[J].Circ Res,2001,89 :e41 -e45.
12.Whitman SC,Ravisankar P,Daugherty A,et al.Interleukin-18 enhances atherosclerosis in apolipoprotein E~(-/-) Mice through release of interferon- γ [J].Circ Res,2002,90 (2 ) :E34-E38.
13.Blankenbergs S, Luc G,Ducimetiere P,et al.Interleukin-18 and the risk of coronary heart disease in European men : the prospective epidemiological study of myocardial Infarction ( PRIME) [J].Circulation ,2003,108(11):2453 - 2459.
14.Hulthe J,McPheat W,Samneg(?)rd A,et al.Plasma interleukin(IL)-l 8 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6[J]. Atheros-clerosis.2006,188(2):450-454.
15.Samantha Paoletti, Vibor Petkovic, Silvia Sebastiani, M.A rich chemokine environment strongly enhances leukocyte migration and activities[J].Blood,2005, 105(6): 3405-3412.
16.Nomura S,Tandon NN,Nakamura T.High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells[J].Atherosclerosis.2001.158(2):277-287.
17.Berdnikovs S,Abdala-Valencia H,McCary C.Isoforms of vitamin E have opposing immunoregulatory functions during inflammation by regulating leukocyte recruitment[J].J Immunol. 2009,82(7):4395-4405.
18.Ruotsalainen E,Vauhkonen I,Salmenniemi U.Markers of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects[J]. Atherosclerosis. 2008,197(l):271-277.
19.Saremi A, Robert J. Anderson, et al.Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis, 2009,203(2): 610-614
20.Aramesh Saremi, Robert J. Anderson, Rosaria Piga, Yuji Naito, Satoshi Kokura. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells.Atherosclerosis, 2007,193(2),328-334
21.George E,Christodoulakos,Irene V.Lambrinoudaki,.Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene.Atherosclerosis, 2007, 193(1):142-150
22.Blanco-Colio LB, Mu(?)oz-Garc(?)a B, Mart(?)n-Ventura J L.Ethanol beverages containing polyphenols decrease nuclear factor kappa-B activation in mononuclear cells and circulating MCP-1 concentrations in healthy volunteers during a fat-enriched dietAtherosclerosis, 2007, 192(2):335-341
23.Tiret L, Godefroy T, Lubos E,et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease [J].Circulation.2005,112(5):643-650.
24.Bis JC,Heckbert SR,Smith NL,et al.Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke[J].Atherosclerosis.2008,198(1):166-173.
25.张承俊,朱兴雷等。辛伐他汀对肿瘤坏死因子α诱导的人脐静脉内皮细胞基质金属蛋白酶9表达的影响。中国动脉硬化杂志,2006年,第一期,50-52
1.Umehara H,Bloom ET,Okazaki T,et al.Fractalkine in vascular biology:from basic research to clinical disease[J].Arterioscler Thromb Vasc Biol.2004,24(1)3440.
2.Hoover DM,Mizoue LS,Handel TM,et al.The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement[J].J Biol Chem.2000,275(30):23187-23193.
3.Nomiyama H,Imai T,Kusuda J,et al.Human chemokines fractalkine (SCYD1),MDC(SCYA22) and TARC(SCYA17) are clustered on chromosome 16q13[J].Cytogenet Cell Genet.1998;81(1):10-11.
4.Fong AM,Robinson LA,Steeber DA,et al.Fractalkine and CX3CR 1mediate a novel mechanism of leukocyte capture,firm adhesion,and activation under physiologic flow[J].J Exp Med.1998,188(8):1413-1419.
5.Imai T,Hieshima K,Haskell C,et al.Identification and molecular characterization of fractalkine receptor CX3CR1,which mediates both leukocyte migration and adhesion[J].Cell.1997,91(11):521-530
6.Yoneda O,Imai T,Goda S,et al.Fractalkine-mediated endothelial cell injury by NK cells[J].J Immunol.2000,164(8):405540-405562
7.Goda S,Imai T,Yoshie O,et al.CX3C-chemokine,fractalkine enhanced adhesion of THP-1 cells to endothelial cells through integrine dependent and independent mechanisms[J].J Immunol.2000,164(8):4313-4320:
8.Loosdregt J, van Oosterhout MF, Bruggink AH,et al.The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response [J]. Circulation. 2006,114(15):1599-1607.
9.Damas JK, Boullier A, Waehre T, et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy[J].Arterioscler Thromb Vasc Biol. 2005, 25(12): 2567-2572
10.Moon SO, Kim W, Sung MJ, et al. Resveratrol suppresses tumor necrosis factor-alpha-induced fractalkine expression in endothelial cells[J]. Mol Pharmacol. 2006,70(1):112-119
11.Ahn SY, Cho CH, Park KG, et al. Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression[J].2004,164(5):1663-1672
12.Sung MJ, Kim W, Ahn SY, et al. Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression[J].Circ Res. 2005,97(9): 880-890
13.McDermott DH,Halcox JP,Schenke WH,et al.Association between polymer-phism in the chemokine receptor CX3CR 1 and coronary vascular endothelial dysfunction and atherosclerosis [J]. Circ Res. 2001,89(5):401-407
14.McDermott DH,Fong AM,Yang Q,et al.Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans [J]. J Clin Invest. 2003,111(8):1241-1250.
15.Moatti D,Faure S,Fumeron F,et al.Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease[J].Blood. 2001,97(7): 1925-1928
16.White PR.Versatile perfusion chamber for living cells and organs[J].Science. 1966,152(730):1758-1760
17.Ditenfass,Osman P.D,Jedrejczyk H.First haemorheological experiment on NASA space shuttle 'Discovery'sts 51-C:Aggregation of red cells[J].Clinical Hemorheology. 1985,.5(5)917-936.
18.Lawrence MB,McIntire LV,Eskin S.G,et al.Effect of flow on polymorpho-nuclear leukocyte/endothelial cell adhesion[J].Blood, 1987,70(6),1284- 1290.
19.Gopalan P. K,Jones DA,McIntire LV,Smith CW.Cell adhesion under hydrodynamic flow conditions, in Current Protocols in Immunology.Wiley, New York. pp. 1996.7.29.1-7.29.23
20.Campbell JJ, Hedrick J, Zlotni kA, et al. Chemokines and the arrest of lymphocytes rolling under flow conditions [J]. Science , 1998 , 279(5349):381-384.
21.Badimon L,Chesebro JH,Badimon JJ.Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation. 1992, 86(6):Ⅲ74-85.
22.von Hundelshausen P, Weber KS, Huo Y.RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation. 2001,103(13):1718-1720.
23.Gill V,Doig C,Knight D.Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin[J].Circulation.2005,112(13): 2031-2039.
24.Yamaguchi J,Kusano KF,Masuo O.Stromal cell-derived factor-1 effects on ex-vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization[J].Circulation.2003,107(9):1322-1328
25.Kaufmann BA, Sanders JM, Davis C.Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1 [J].Circulation. 2007,116(3):276-284
26.Luscinskas, FW,Ding H,Lichtman A.H.P-selectin and VCAM-1 mediate rolling and arrest of CD4+ T-lymphocytes on TNF-activated vascular endothelium under flow[J].Exp.Med. 1995, 181(6), 1179-1186.
27.Kadono T,Venturi GM,Steeber DA.Leukocyte rolling velocities and migration are optimized by cooperative L-selectin and intercellular adhesion molecule-1 functions.J Immunol. 2002,169(8):4542-4250.
28.Bengtson P,Lundblad A,Larson GPolymorphonuclear leukocytes from individuals carrying the G329A mutation in the alpha 1,3-fucosyltransferase Ⅶ gene (FUT7) roll on E- and P-selectins..J Immunol. 2002,169(7):3940-3946.
29.Ulfman LH, Joosten DP, van der Linden JA .IL-8 induces a transient arrest of rolling eosinophils on human endothelial cells.J Immunol. 2001,166(1):588-595.
30.Fitzhugh DJ, Naik S, Caughman SW, Hwang ST.Cutting edge:C-C chemokine receptor 6 is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells under physiologic flow conditions in vitro[J].J Immunol. 2000,165(12):6677-6681.
1.Bazan JF,Bacon KB,Hardiman G,et al.A new class of membrane bound chemokine with a CX3C motif[J].Nature 1997,385(6617):640-644.
2.Werb Z,Yan Y,et al.A cellular striptease act[J].Science.1998,282(5392):1279-1280.
3.Pan Y,Lloyd C,Zhou H,et al.Neurotactin,a membrane-anchored chemokine upregulated in brain inflammation[J].Nature.1997,387(6633):611-617
4.Hoover DM,Mizoue LS,Handel TM,et al.The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement.J Biol Chem.2000 Jul 28;275(30):23187-23193.
5.Nomiyama H,Imai T,Kusuda J,et al.Human chemokines fractalkine(SCYD 1),MDC(SCYA22) and TARC(SCYA17) are clustered on chromosome 16q13[J]. Cytogenet Cell Genet. 1998;81(1):10-11.
6.Nishiyori A,Minami M,Ohtani Y,et al. Localization of fractalkine and CX3CRlmRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia FEBS Lett [J]. 1998,429(2):167-172.
7.Harrison JK, Jiang Y, Chen S,et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1 expressing microglia [J]. ProcNatlAcad Sci U S A. 1998,95(18): 10896-10901
8.Foussat A, Coulomb-L'Hermine A, Gosling J. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human.Eur J Immunol. 2000,30(1):87-97.
9.Garcia GE,Xia Y,Chen S,et al. NF-cappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1 beta,TNF-apha,and LPS [J]. J Leuk oc Biol. 2000,67(4):577-584.
10.Cambien B, Pomeranz M, Schmid Antomarchi H,et al. Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion [J].Blood. 2001,97(7):2031-2027
11.Kansra V,Groves C,Gutierrezamos JC,et al.Phosphatidylinositol cinase depen- dent extracellular calcium influx is essential for CX(3)CR1 mediated activation of the mitogen activated protein kinase cascade[J].J Biol Chem.2001,276 (34):318-331.
12.Campbell JJ,QinS,BaconKB,et al.Biology of chemokin and classical chemoattractant receptors:differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells[J] J Cell Biol,1996,134(1):255-266.
13.Combadiere C,SalzwedelK,Smith ED,et al.Identification of CX3CR1 :A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor forHIV-1 [J].J Biol Chem,1998,273(37):23799-23804.
14.Combadiere C,Ahuja SK,Murphy PM,et al. Cloning,chromosomal localization,and RNA expression of a human beta chemokine receptor- likegene[J].DNA Cell Biol,1995,14 (8): 673 -680.
15.Baggiolini M,Dewald B,Moser B,et al.Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines [J] Adv Immunol,1994,55:97-179.
16.Baggiolini M,Dewald B,Moser B,et al.Human chemokines An update[J]. Annu Rev Immunol, 1997,15:675-70
17.Mizoue LS,Bazan JF,Johnson EC,et al.Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1 [J]. Biochemistry,1999,38(5):1402-1410
18.Garin A, Pellet P, Deterre P,et al. Cloning and functional characterization of the human fractalkine receptor promoter regions[J].Biochem J.2002,368 (3):753-760
19.Umehara H, Bloom ET, Okazaki T,et al. Fractalkine in vascular biology: from basic research to clinical disease[J].Arterioscler Thromb Vase Biol. 2004 ,24(1) 3440-3445
20.Harrison JK, Fong AM, Swain PA,et al. Mutational analysis of the fractalkinechemokine domain. Basic amino acid residues differentially contribute to CX3CR1 binding,signaling,and cell adhesion[J] J Biol Chem.2001,276 (24):216-232
21.Fong AM, Robinson LA, Steeber DA,et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture,firm adhesion,and activation under physiologic flow [J]. J Exp Med. 1998,188(8):14139-14145
22.Imai T,Hieshima K,Haskell C,et al.Identification and molecular characterization of fractalkine receptor CX3CR1,which mediates both leukocyte migration and adhesion [J]. Cell. 1997,91(4):521-530
23.Fong AM, Erickson HP, Zachariah JP,et al. Ultrastructure and function of the fractalkine mucin domain in CX(3)C chemokine domain presentation [J]. J Biol Chem. 2000,275(6):3781-3786.
24.Yoneda O, Imai T, Goda S,et al. Fractalkine-mediated endothelial cell injury by NK cells [J]. J Immunol. 2000,164(8):4055-4062
25.Goda S, Imai T, Yoshie O,et al. CX3C-chemokine, fractalkine enhanced adhesion of THP-1 cells to endothelial cells through integrine dependent and independent mechanisms [J]. J Immunol. 2000 ,164(8):4313-4320
26.Bursill CA,Channon KM,Greaves DR,et al.The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics[J]. Curr Opin Lipidol. 2004,15(2):145-149.
27.Loosdregt J, van Oosterhout MF, Bruggink AH,et al.The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response [J]. Circulation. 2006,114(15):1599-1607.
28.Boisvert WA. Modulation of atherogenesis by chemokines[J].Trends Cardio-vasc Med. 2004,14(4): 161-169
29.Lutgens E,Faber B,Schapira K,et al.Gene profiling in atherosclerosis reveals a key role for small inducible cytokines:validation using a novel monocyte chemoattractant protein monoclonal antibody[J].Circulation.2005,111(25):3443-3452.
30.Schulz C,Schafer A,Stolla M,et al.Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets[J].Circulation.2007,116 (7):764-773.
31.Lesnik P, Haskell CA, Charo JF,et al. Reveals a role for Decreased atherosclerosis in CX3CR1~(-/-) pucefractalkine inrogenesis[J].J Clin Invest.2003, 1119 (9):333-340.
32.Combadiere C, Potteaux S, Gao JL,etal .Decreased atherosclerotic lesion formation in CX3CRl/apolipoprotein E double knockout mice [J]. Circulation. 2003 ,107(7):1009-1016.
33.Saederup N,Chan L,Lira SA,Charo IF,et al. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2~(-/-) mice: evidence for independent chemokine functions in atherogenesis [J].Circulation. 2008,117(13):1642-1648.
34.Philippe L,Christopher A,Haskell T et al.Decreased atherosclerosis in CX3CR1~(-/-) mice reveals a role for fractalkine in atherogenesis [J]. J Clin Invest. 2003 ,111(3): 333-340.
35.McDermott DH,Halcox JP,Schenke WH,et al.Association between polymorphism in the chemokine receptor CX3CR 1 and coronary vascular endothelial dysfunction and atherosclerosis [J]. Circ Res. 2001,89(5):401-407
36.McDermott DH,Fong AM,Yang Q,et al. Chemokine receptor mutant CX3CR1 -M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans [J]. J Clin Invest. 2003,111(8):1241-1250.
37.Moatti D,Faure S,Fumeron F,et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease [J]. Blood. 2001,97(7): 1925-1928
38.Okamura H,Nagata K,Komatsu T,et al. A novel costimulatorv factor for gamma interferon induction found in the livers of mice causes endotoxic shock [J] . Infect Immun,1995,63(10):3966-3972
39.Kohno K, Kataok A ,Ohtsuki T , et al.IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12 [J].J Immunol ,1997,158(7):1541-1550.
40.Lebel-Binay S,Berger A,Zinzindohoue F,et al.Interleukin-18:biological properties and clinical implications [J].Eur Cytokine Netw,2000,11(1): 15-21
41.KohnoK,KurimotoM,et al.hiterleukinl8,a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both [JJ.Clin Immunol Immunopathol,1998,86(1):11-18
42.Berclaz PY,Shibata Y,Whitsett JA,et al. GM-CSF,viaPU.1,regulates alveolar macrophage Fcgamma R-mediated phagocytosis and the IL-18/IFN-gamma-mediated molecular connection between innate and adaptive immunity in the lung [J].Blood, 2002,100(12):4193-4199
43.Heath VL,Kurata H,Lee HJ,et al.Checkpoints in the regulation of T helper 1 responses [J].Curr Top Microbiol Immunol,2002,266(6):23-27
44.Mallat Z,Corbaz A,Scoazec A,et al.Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability[J].Circulation,2001,104(7): 1598-1603.
45.Tenger C,Sundborger A,Jawien J,et al.IL-18 accelerate atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells[J].Arterioscler Thromb Vasc Biol 2005,25:791-796.
46.Mallat Z,Corbaz A,Scoazec A,et al.Interleukin-18/ interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability[J].Circ Res,2001,89:e41-e45.
47.Maffia P,Grassia G,Di Meglio P,et al.Neutralization of interleukin-18 inhibits neointimal formation in a rat model of vascular injury[J].Circulation.2006,114 (5):430-437
48.Kretowski A,Kinalska I,et al.Serum levels of interleukin-18 a potential marker of cardiovascular death-could be determined by genetic predisposition[J]. Circulation. 2003,107(22):e206-e207
49.Tiret L,Godefroy T,Lubos E,et al.Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease [J].Circulation. 2005,112(5):643-650.
50.Bis JC,Heckbert SR,Smith NL,et al.Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke[J].Atherosclerosis. 2008,198(1):166-173.
51.Blankenberg S,Tiret L ,Bickel C,et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina [J].Circulation,2002,106(8):24-30.
52.Blankenberg S,Luc G,Ducimetiere P,et al.Interleukin-18 and the risk of coronary heart disease in European men:the prospective epidemiological study of myocarndial Infarction (PRIME) [J].Circulation,2003,108(5):2453-2459.
53.Chalikias GK,Tziakas DN,Kaski JC,et al.Interleukin-18: interleukin-10 ratio and in hospital adverse events in patients with acute coronary syndrome[J]. Atherosclerosis. 2005,182(1):135-143.
54.Tziakas DN,Chalikias GK,Kaski JC,et al.Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients:a factor ana- lysis approach[J]. Atherosclerosis. 2007,193(l):196-203.
55.Hulthe J, McPheat W, Samneg(?)rd A,et al.Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6[J]. Atherosclerosis. 2006,188(2):450-454.
56.Samneg(?)rd A, Hulthe J, Silveira A,et al.Gender specific associations between matrix met alloproteinases and inflammatory markers in post myocardial infarction patients[J].Atherosclerosis. 2009,202(2):550-556.
57.Hernesniemi JA,Karhunen PJ,Rontu R,et al.Interleukin-18 promoter polymor-phism associates with the occurrence of sudden cardiac death among Caucasian males:the Helsinki Sudden Death Study [J].Atherosclerosis.2008,196(2): 643-649.
58.Gupta S,Pablo AM Jiang X,et al. IFN-gamma potentiates atherosclerosis in Apo E knock out mice[J].J Clin Invest,1997,99(7):2752-2761.
59.Yoshimoto T,Takeda K,Tanaka T,et al.IL-12 up-regulates IL-18 receptor expression on T cells Thl cells and B cells.syn-ergism with IL-18 for IFN- γ production[J].J Immunol, 1998,161(7):3400-3407.
60.Whitman SC,Ravisankar P,Daugherty A,et al.Interleukin-18 enhances atherosclerosis in apolipoprotein E~(-/-) Mice through release of interferon- Y [J].Circ Res,2002, 90 (2) :E34-E38.
61.Elhage R,Jawien J,Rudling M,et al.Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice[J].CardiovascRes,2003,59(1):234-240.
62.de Nooijer R,vonder Thusen JH,Verkleij CJ,et al.Over expression of IL-18 decreases intimal collagen contentand promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice[J].Arterioscler Thromb Vasc Biol,2004,24(12):2313-2319.
63.Sa har S,Dwarakanath RS,Reddy MA,et al.Angiotensin Ⅱ enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells:a novel crosstalk in the pathogenesis of atherosclerosis[J].Circ Res,2005,96(4): 1064-1071.
64.Mitsuoka H, Kume N, Hayashida K,et al.Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1 (sLOX-1) [J]. Atherosclerosis. 2009,202(1):176-182.